JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines

被引：0
|
作者：
P Nauroy
F Delhommeau
F Baklouti
机构：
[1] mRNA Metabolism in Normal and Pathological Cells,
[2] CNRS UMR 5534,undefined
[3] Université Lyon 1,undefined
[4] Sorbonne Universités,undefined
[5] UPMC Univ Paris 06,undefined
[6] GRC no. 07,undefined
[7] Groupe de Recherche Clinique sur les Myéloproliférations Aiguës et Chroniques MyPAC,undefined
[8] AP-HP,undefined
[9] Hôpital Saint-Antoine,undefined
[10] Laboratoire d'Hématologie,undefined
[11] Sorbonne Universités,undefined
[12] UPMC Univ Paris 06,undefined
[13] UMR_S 938,undefined
[14] CDR Saint-Antoine,undefined
[15] INSERM,undefined
[16] UMR_S 938,undefined
[17] CDR Saint-Antoine,undefined
[18] Current address: Institut de Génomique Fonctionnelle de Lyon,undefined
[19] Ecole Normale Supérieure,undefined
[20] Lyon,undefined
[21] France,undefined
来源：
Blood Cancer Journal | 2014年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：e222 / e222
相关论文
共 50 条
  • [41] Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
    Pedersen, Kasper Monsted
    Colak, Yunus
    Hasselbalch, Hans Carl
    Bojesen, Stig Egil
    Nordestgaard, Borge Gronne
    ECLINICALMEDICINE, 2020, 22
  • [42] Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
    Garbers, Christoph
    Rose-John, Stefan
    ECLINICALMEDICINE, 2020, 22
  • [43] Interferon Alpha May Improve the prognosis of Advanced Myeloproliferative Neoplasm Patients with JAK2V617F Mutations
    Liu Xiaoli
    Ding, Li
    Xu, Na
    Huang, Bintao
    Zhou, Xuan
    Lu Qisi
    Huang, Jixian
    BLOOD, 2014, 124 (21)
  • [44] Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm
    Castiglione, Melissa
    Jiang, Ya-Ping
    Mazzeo, Christopher
    Lee, Sandy
    Chen, Juei-Suei
    Kaushansky, Kenneth
    Yin, Wei
    Lin, Richard Z.
    Zheng, Haoyi
    Zhan, Huichun
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (12) : 3359 - 3370
  • [45] The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
    Holmstrom, M. O.
    Hjortso, M. D.
    Ahmad, S. M.
    Met, O.
    Martinenaite, E.
    Riley, C.
    Straten, P.
    Svane, I. M.
    Hasselbalch, H. C.
    Andersen, M. H.
    LEUKEMIA, 2017, 31 (02) : 495 - 498
  • [46] JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms
    Lin, Chi Hua Sarah
    Kaushansky, Kenneth
    Zhan, Huichun
    BLOOD CELLS MOLECULES AND DISEASES, 2016, 62 : 42 - 48
  • [47] JAK2V617F-Mutant Vascular Niche Promotes JAK2V617F Clonal Expansion in Myeloproliferative Neoplasms
    Zhan, Huichun
    Lin, Chi Hua Sarah
    Segal, Yarden
    Kaushansky, Kenneth
    BLOOD, 2016, 128 (22)
  • [48] The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
    M O Holmström
    M D Hjortsø
    S M Ahmad
    Ö Met
    E Martinenaite
    C Riley
    P Straten
    I M Svane
    H C Hasselbalch
    M H Andersen
    Leukemia, 2017, 31 : 495 - 498
  • [49] Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm
    Yang, Yue
    Akada, Hajime
    Nath, Dipmoy
    Hutchison, Robert E.
    Mohi, Golam
    BLOOD, 2016, 127 (26) : 3410 - 3423
  • [50] Red cell microvesicles and arterial vasospasm in JAK2V617F mutated myeloproliferative disorders
    Poisson, Johanne
    Tanguy, Marion
    Rautou, Pierre-Emmanuel
    M S-MEDECINE SCIENCES, 2021, 37 (04): : 329 - 331
12345